Ernexa Therapeutics Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
1035 CAMBRIDGE STREET, CAMBRIDGE, MA, 02141
Mailing Address
10531 4S COMMONS DRIVE, SAN DIEGO, CA, 92127
Phone
(617) 798-6700
Fiscal Year End
1231
EIN
311103425
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| S-3/A Shelf registration amendment | March 24, 2026 | View on SEC |
| 8-K Current report of material events | March 20, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | March 16, 2026 | View on SEC |
| 10-K Annual financial report | March 13, 2026 | View on SEC |
| 8-K Current report of material events | February 26, 2026 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 17, 2026 | View on SEC |
| 8-K Current report of material events | February 11, 2026 | View on SEC |
| 424B5 Prospectus supplement | February 10, 2026 | View on SEC |
| S-1/A IPO registration amendment | February 5, 2026 | View on SEC |
Annual Reports
10-K
March 13, 2026
- Successfully completed Phase 1 clinical trial for ERNA-001 in Q3 2025, showing favorable safety and preliminary effectiveness.
- Secured a foundational patent for its gene therapy delivery system in Q2 2025, strengthening intellectual property.
Material Events
8-K
Financial Distress
March 20, 2026
High Impact
- Ernexa received a Nasdaq delisting warning on March 18, 2026, due to its stock price falling below $1.00 for 30 business days.
- A recent reverse stock split means Ernexa will not receive the standard 180-day grace period to regain compliance.
Insider Trading
BUY
1 insiders
1 recent transactions
View Insider Trading Dashboard
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.